University of Miami – The Saporta CMT Stem Cell Laboratory is a state-of-the-art facility working to develop iPSc’s for CMT4A (GDAP1) and CMT6 (C12orf65, also known as MTRFR gene).

Both subtypes of CMT require models to test various therapeutics. HNF has developed these models to support multiple collaborations amongst Dr. Saporta and within HNF’s TRIAD research partnerships.

Learn more on this topic

Latest News and Related Blog Posts

2024 CMT Roadshow Coming to a City Near You?

2024 CMT Roadshow Coming to a City Near You?

Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank

Cambridge-led natural history study identifies MTRFR/C12orf65 deficiency to improve diagnosis and therapy development

Cambridge-led natural history study identifies MTRFR/C12orf65 deficiency to improve diagnosis and therapy development

This research will potentially show a method that may be quicker and better at identifying baseline disease phenotypes to support research and clinical trials. Cambridge-led retrospective natural history study funded by the Hereditary Neuropathy Foundation identifies...

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.